Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Continuous fever

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38 result(s) found for: Continuous fever. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-004281-10 Sponsor Protocol Number: PT/11/2017 Start Date*: 2018-01-10
    Sponsor Name:Department of Pediatric oncology, Aarhus University hospital
    Full Title: Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia
    Medical condition: Pediatric oncology patients with fever
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10051312 Neutropenic fever LLT
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    20.0 100000004864 10007050 Cancer LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-000466-33 Sponsor Protocol Number: PT/11/2015 Start Date*: 2016-03-22
    Sponsor Name:Department of Pediatric oncology, Aarhus University hospital
    Full Title: Pharmacokinetics and pharmacodynamics of Piperacillin-Tazobactam (PT) in pediatric oncology patients with fever and neutropenia.
    Medical condition: Pediatric oncology patients with fever and neutropenia
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10007050 Cancer LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000969-37 Sponsor Protocol Number: AN-SCD1121 Start Date*: 2007-10-05
    Sponsor Name:Anthera Pharmaceuticals Incorporated
    Full Title: IMPACTS Trial: Investigation of the Modulation of Phospholipase in Acute Chest Syndrome (Dose Escalation Study: Varespladib Infusion [A-001] for the Prevention of Acute Chest Syndrome in At-Risk ...
    Medical condition: Acute Chest Syndrome (ACS) in At-Risk patients with Sickle Cell Disease (SCD) and Vaso-occlusive Crisis (VOC)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051895 Acute chest syndrome LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-004433-17 Sponsor Protocol Number: 124210 Start Date*: 2020-02-18
    Sponsor Name:MRC CTU at UCL
    Full Title: Multi-centre, randomised, open-label, blinded endpoint assessed, trial of corticosteroids plus intravenous immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin for prevention of coronary arte...
    Medical condition: Kawasaki Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10023320 Kawasaki's disease PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) EE (Completed) SE (Completed) FI (Completed) ES (Ongoing) DE (Completed) NL (Completed) IT (Completed) AT (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021621-12 Sponsor Protocol Number: NAI114373 Start Date*: 2010-12-01
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: NAI114373: A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of ...
    Medical condition: hospitalised adults and adolescents with influenza
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) FR (Completed) GB (Completed) HU (Completed) NL (Completed) CZ (Completed) NO (Completed) DK (Completed) GR (Completed) BE (Completed) PL (Completed) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-006908-32 Sponsor Protocol Number: PNEUMONOVA Start Date*: 2022-07-01
    Sponsor Name:Sonia Luque Pardos
    Full Title: Intrapulmonary penetration of ceftolozane / tazobactam and ceftazidime / avibactam administered in continuous infusion in critically ill patients with nosocomial pneumonia
    Medical condition: Nosocomial pneumonia
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004862 10052596 Nosocomial pneumonia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002822-21 Sponsor Protocol Number: ARCHIE001 Start Date*: 2013-10-10
    Sponsor Name:University of Oxford
    Full Title: The early use of Antibiotics for at Risk CHildren with InfluEnza in primary care (ARCHIE): a double-blind randomised placebo-controlled trial
    Medical condition: Influenza or influenza-like illness
    Disease: Version SOC Term Classification Code Term Level
    16.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000407-20 Sponsor Protocol Number: APHP201454 Start Date*: 2021-09-22
    Sponsor Name:ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
    Full Title: Treatment of nonsevere sporadic Hemophagocytosis Lymphohistiocytosis (HLHs) with ITACITINIB: a phase II prospective trial.
    Medical condition: Adults patients having non severe sporadic Hemophagocytosis Lymphohistiocytosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-001754-21 Sponsor Protocol Number: 2020-23 Start Date*: 2020-05-19
    Sponsor Name:Assistance Publique Hôpitaux de Marseille
    Full Title: An open prospective randomized therapeutic trial using ANAKINRA or TOCILIZUMAB alone or in combination with RUXOLITINIB in severe stage 2b and 3 COVID-19 disease
    Medical condition: COVID-19-associated disease
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-005526-29 Sponsor Protocol Number: VP-VLY-686-3501 Start Date*: 2021-03-31
    Sponsor Name:Vanda Pharmaceuticals Inc.
    Full Title: ODYSSEY: A randomized, double-blind, placebo-controlled study to investigate the efficacy of tradipitant in treating inflammatory lung injury and improving clinical outcomes associated with severe ...
    Medical condition: inflammatory lung injury associated with severe COVID-19 infection
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084383 Novel COVID-19-infected pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001086-34 Sponsor Protocol Number: IGG-PRINTO-001 Start Date*: 2005-10-21
    Sponsor Name:Istituto Giannina Gaslini-PRINTO
    Full Title: A randomised trial of 6 months versus 12 months withdrawal of methotrexate in patiebts with juvenile idiopathic arthritis in clinical remission.Ensayo aleatorizado de retirada de Metotrexate a los ...
    Medical condition: The present study was designed for the follow up of two groups of patients with JIA, in whom remission was achieved using MTX. In group 1 treatment with MTX will be discontinued as early as 6 month...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-002482-34 Sponsor Protocol Number: GAM10-10 Start Date*: 2020-05-21
    Sponsor Name:Octapharma USA
    Full Title: Efficacy and safety of Octagam 10% therapy in COVID-19 patients with severe disease progression
    Medical condition: COVID-19
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2013-001849-13 Sponsor Protocol Number: 2013/cardio3 Start Date*: 2013-07-09
    Sponsor Name:ASLTO2-Maria Vittoria Hospital Cardiology
    Full Title: AnakInRa Treatment of Recurrent Idiopathic Pericarditis
    Medical condition: idiopathic recurrent pericarditis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-002708-28 Sponsor Protocol Number: REDIV/002/17 Start Date*: 2018-02-23
    Sponsor Name:Alfasigma S.p.a
    Full Title: Rifaximin delayed release (400 mg tablet) for the prevention of recurrent acute diverticulitis and diverticular complications. A phase II, multicenter, double-blind, placebo-controlled, randomized ...
    Medical condition: Prevention of recurrent acute diverticulitis and diverticular complications
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10052812 Acute diverticulitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Completed) HU (Completed) FR (Completed) NL (Completed) GB (GB - no longer in EU/EEA) PT (Completed) IT (Prematurely Ended) RO (Completed)
    Trial results: View results
    EudraCT Number: 2004-004051-19 Sponsor Protocol Number: IM101-042 Start Date*: 2005-05-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase IIB, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept in Combination Therapy with Glucocorticosteroids vs. Placebo plus Gluc...
    Medical condition: SYSTEMIC LUPUS ERYTHEMATOSUS, NOS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) SE (Prematurely Ended) BE (Completed) AT (Completed) IT (Prematurely Ended)
    Trial results: Removed from public view
    EudraCT Number: 2005-005975-13 Sponsor Protocol Number: V00114 CP 201 Start Date*: 2006-04-25
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis.
    Medical condition: Prospective, multicentric, international, randomised, double-blind trial in six parallel groups: 4 doses of the test product, active control and placebo. This study is intended to evaluate the ef...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004571-41 Sponsor Protocol Number: RBMinCovid19 Start Date*: 2021-02-23
    Sponsor Name:Cyxone AB
    Full Title: A Randomized, Placebo Controlled, Double Blind Study to Evaluate the Safety and Efficacy of Rabeximod Compared to Standard of Care in Patients With Moderate Coronavirus Disease (COVID-19)
    Medical condition: Coronavirus Disease (COVID-19)
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004862 10084401 COVID-19 respiratory infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) HU (Prematurely Ended) LV (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001379-66 Sponsor Protocol Number: CHMI-trans1 Start Date*: 2016-04-28
    Sponsor Name:Radboud university medical center
    Full Title: Controlled Human Malaria Infection study to assess gametocytaemia and mosquito transmissibility in participants challenged with Plasmodium falciparum by sporozoite challenge to establish a model fo...
    Medical condition: Plasmodium falciparum malaria
    Disease: Version SOC Term Classification Code Term Level
    19.0 10022891 - Investigations 10070881 Malaria antibody test positive PT
    19.0 100000004862 10016171 Falciparum malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002512-40 Sponsor Protocol Number: 201023 Start Date*: 2016-12-05
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Phase II, global, randomized study to evaluate the efficacy and safety of Danirixin (GSK1325756) co-administered with a standard-of-care antiviral (oseltamivir), in the treatment of adults hospit...
    Medical condition: Hospitalized influenza
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) NL (Prematurely Ended) FR (Completed)
    Trial results: View results
    EudraCT Number: 2017-004005-40 Sponsor Protocol Number: NL63552.000.17 Start Date*: 2018-02-15
    Sponsor Name:Radboud university medical center
    Full Title: Controlled Human Malaria Infection study to assess gametocytaemia and mosquito transmissibility in participants challenged with Plasmodium falciparum by sporozoite challenge to establish a model fo...
    Medical condition: Plasmodium falciparum malaria
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004848 10064864 Malaria antibody positive LLT
    20.0 100000004862 10016171 Falciparum malaria LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 18 17:47:40 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA